Equity Profile

IONS

Ionis Pharmaceuticals, Inc.

Health CareBiotechnology$12.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for various diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IONS Q2-2026 Earnings Preview

Context

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for various diseases. With a market cap of $12 billion, Ionis is significant in the health care sector, particularly in genetic and rare diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In Q1-2026, Ionis reported an EPS of -$0.56, outperforming expectations by 37.36%. The stock reacted positively, gaining 4.25% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Ionis are mixed, with investors eager to see if the company can maintain its trend of beating EPS estimates.

Bull Case

If Ionis continues to surprise with better-than-expected earnings, it could signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, if Ionis fails to meet expectations, it may raise concerns about its growth prospects and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in determining whether Ionis can continue its trend of beating estimates and instill confidence in investors.

How is revenue growth tracking for the upcoming quarter?

Revenue growth will indicate the company's ability to expand its market share and validate its product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ionis's ability to leverage its recent product developments, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

Ionis has consistently beaten EPS estimates, suggesting operational strength.

The options market is pricing in a larger move than historical averages, indicating potential for significant surprises.

Key Risk

If Ionis reports an EPS better than -$0.50, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Ionis's ability to sustain its recent performance and growth amidst competitive pressures.

Bull Confirmed If

An EPS of -$0.50 or better would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$0.75 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.45%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±9.5% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

23.1%

Calls (20K)P/C Ratio: 0.06Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

16,494 sh

4 insiders

Net

$1.2M

Net selling

Most Active Insiders· 5 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests a potential stock increase of around +1.92%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If Ionis misses expectations, history suggests a potential decline of around -5.29%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market demand for existing therapies.
3Insights into the pipeline for future drug developments.
4Details on partnerships or collaborations that may enhance growth.
5Guidance on operational costs and their impact on future profitability.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for various diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IONS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In Q1-2026, Ionis reported an EPS of -$0.56, outperforming expectations by 37.36%. The stock reacted positively, gaining 4.25% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Ionis are mixed, with investors eager to see if the company can maintain its trend of beating EPS estimates.

Bull Case

If Ionis continues to surprise with better-than-expected earnings, it could signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, if Ionis fails to meet expectations, it may raise concerns about its growth prospects and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be crucial in determining whether Ionis can continue its trend of beating estimates and instill confidence in investors.

How is revenue growth tracking for the upcoming quarter?

Revenue growth will indicate the company's ability to expand its market share and validate its product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Ionis's ability to leverage its recent product developments, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

Ionis has consistently beaten EPS estimates, suggesting operational strength.

The options market is pricing in a larger move than historical averages, indicating potential for significant surprises.

Key Risk

If Ionis reports an EPS better than -$0.50, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Ionis's ability to sustain its recent performance and growth amidst competitive pressures.

Bull Confirmed If

An EPS of -$0.50 or better would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$0.75 would confirm the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.45%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±9.5% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

23.1%

Calls (20K)P/C Ratio: 0.06Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

16,494 sh

4 insiders

Net

$1.2M

Net selling

Most Active Insiders· 5 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests a potential stock increase of around +1.92%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If Ionis misses expectations, history suggests a potential decline of around -5.29%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on market demand for existing therapies.
3Insights into the pipeline for future drug developments.
4Details on partnerships or collaborations that may enhance growth.
5Guidance on operational costs and their impact on future profitability.